Advertisement

Drug-Induced Liver Injury (DILI) Classification and Its Application on Human DILI Risk Prediction

  • Shraddha Thakkar
  • Minjun Chen
  • Huixiao Hong
  • Zhichao Liu
  • Hong Fang
  • Weida TongEmail author
Protocol
Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Abstract

Drug-induced liver injury (DILI) is one of the primary reasons for drugs being terminated in premarket studies or being withdrawn from the market after approval. Many new methodologies have been examined to improve DILI prediction, including high-throughput/high-content screening assays, in silico approaches and toxicogenomics, all of which rely on a truth set of drugs with well-defined DILI potential. However, defining a drug’s DILI risk is on varying interpretations, leading to differing classification schemes. Even when the same drug list is employed, variability in scheme affects predictive variables and models which lead to disparate risk prediction. Each model imbeds truth and knowledge in a different manner and context. An integrative approach melding models and variables should yield a system with enhanced prediction accuracy and better characterized mechanisms of action. Toward such an integrative predictor, we present four different classification schemes, i.e., an FDA labeling data-based approach (DILIrank dataset), a clinical evidence-based approach (LiverTox dataset), literature-based approaches (Greene and Xu datasets), and a registry-based approach (Suzuki dataset). Comparative analyses showed good general agreement between these approaches, with the most substantial difference observed between in silico models for drug-centric classification methods (i.e., drug-labeling and literature based approaches) versus clinical evidence-based methods (i.e., case reports and registry based approaches). The results suggest that substantial benefits can be obtained by consolidating various classification schemes to generate a larger dataset imbedding more diverse knowledge, and especially the new data streams from emerging technologies.

Key words

Drug-induced liver injury Risk assessment DILI classification Rule-of-two model DILIscore model 

Notes

Disclaimer

The views presented in this chapter do not necessarily reflect current or future opinion or policy of the US Food and Drug Administration. Any mention of commercial products is for clarification and not intended as an endorsement.

References

  1. 1.
    Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, Tong W (2014) Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomarkers 8(2):201–213CrossRefGoogle Scholar
  2. 2.
    Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711–716PubMedCrossRefGoogle Scholar
  3. 3.
    Brody T (2016) Clinical trials: study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines. Academic Press, Cambridge, MACrossRefGoogle Scholar
  4. 4.
    Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W et al (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32(1):56–67PubMedCrossRefGoogle Scholar
  5. 5.
    Raunio H (2011) In silico toxicology-non-testing methods. Front Pharmacol 2:33PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Collins FS, Gray GM, Bucher JR (2008) Transforming environmental health protection. Science (New York, NY) 319(5865):906CrossRefGoogle Scholar
  7. 7.
    Dix DJ, Houck KA, Martin MT, Richard AM, Setzer RW, Kavlock RJ (2007) The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci 95(1):5–12PubMedCrossRefGoogle Scholar
  8. 8.
    Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 21(4):648–653PubMedCrossRefGoogle Scholar
  9. 9.
    Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ (2010) Developing structure−activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 23(7):1215–1222PubMedCrossRefGoogle Scholar
  10. 10.
    Guo JJ, Wigle PR, Lammers K, Vu O (2005) Comparison of potentially hepatotoxic drugs among major US drug compendia. Res Social Adm Pharm 1(3):460–479PubMedCrossRefGoogle Scholar
  11. 11.
    Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, Kenna JG (2014) A correlation between the in vitro drug toxicity of drugs to cell lines which express human P450s and their propensity to cause liver injury in humans. Toxicol Sci 137:189–211PubMedCrossRefGoogle Scholar
  12. 12.
    Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105(1):97–105PubMedCrossRefGoogle Scholar
  13. 13.
    Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W (2011) FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 16(15):697–703PubMedCrossRefGoogle Scholar
  14. 14.
    Björnsson ES, Hoofnagle JH (2016) Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology 63(2):590–603PubMedCrossRefGoogle Scholar
  15. 15.
    Ekins S, Williams AJ, Xu JJ (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug Metab Dispos 38(12):2302–2308PubMedCrossRefGoogle Scholar
  16. 16.
    Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, Freston JW (2010) Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase™. Drug Saf 33(6):503–522PubMedCrossRefGoogle Scholar
  17. 17.
    Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ (2013) LiverTox: a website on drug-induced liver injury. Hepatology 57(3):873–874PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W (2011) Translating clinical findings into knowledge in drug safety evaluation-drug induced liver injury prediction system (DILIps). PLoS Comput Biol 7(12):e1002310PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Yu K, Geng X, Chen M, Zhang J, Wang B, Ilic K, Tong W (2014) High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos 42(4):744–750PubMedCrossRefGoogle Scholar
  20. 20.
    Chen M, Borlak J, Tong W (2013) High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58(1):388–396PubMedCrossRefGoogle Scholar
  21. 21.
    Chen M, Hong H, Fang H, Kelly R, Zhou G, Borlak J, Tong W (2013) Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs. Toxicol Sci 136(1):242–249PubMedCrossRefGoogle Scholar
  22. 22.
    Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI (2015) Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 63(2):503–514PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Kaplowitz N (2013) Avoiding idiosyncratic DILI: two is better than one. Hepatology 58(1):15–17PubMedCrossRefGoogle Scholar
  24. 24.
    Waring MJ (2009) Defining optimum lipophilicity and molecular weight ranges for drug candidates—molecular weight dependent lower logD limits based on permeability. Bioorg Med Chem Lett 19(10):2844–2851PubMedCrossRefGoogle Scholar
  25. 25.
    Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N (2008) Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 47(6):2003–2009PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Walgren JL, Mitchell MD, Thompson DC (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 35(4):325–361CrossRefGoogle Scholar
  27. 27.
    Uetrecht J (2001) Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Devel 4(1):55–59PubMedGoogle Scholar
  28. 28.
    Chen M, Borlak J, Tong W (2016) A model to predict severity of drug-induced liver injury in humans. Hepatology 64(3):931–940PubMedCrossRefGoogle Scholar
  29. 29.
    Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24(9):1345–1410PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Thakkar S, Chen M, Fang H, Liu Z, Roberts R, Tong W (2017) The liver toxicity knowledge base (LTKB) and drug-induced liver injury (DILI) classification for assessment of human liver injury. Expert Rev Gastroenterol Hepatol 9:1–8. https://doi.org/10.1080/17474124.2018.1383154 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Shraddha Thakkar
    • 1
  • Minjun Chen
    • 1
  • Huixiao Hong
    • 1
  • Zhichao Liu
    • 1
  • Hong Fang
    • 2
  • Weida Tong
    • 1
    Email author
  1. 1.Division of Bioinformatics and Biostatistics, National Center for Toxicological ResearchU.S. Food and Drug AdministrationJeffersonUSA
  2. 2.Office of Scientific Coordination, National Center for Toxicological ResearchU.S. Food and Drug AdministrationJeffersonUSA

Personalised recommendations